Liability
Table of Contents
Liability
As a small business owner, you might owe money to suppliers, staff members, and the government. In your accounting records, you must maintain records of the debts owed by your company. Mark your debts as liabilities to keep track of the money you owe.
Liabilities are past-due debts owed by your company to another company, group, vendor, worker, or government body. Debts are acquired via routine company operations.
What is a liability?
The amount of debt owed by a business to settle previous transactions is referred to as liabilities. This money may belong to the corporation rather than its lenders, banks, or other lenders or financial organisations. The balance statement lists these as credits in the order of payment terms.
Any business organisation’s liability is a crucial component and is frequently a reliable indicator of how well-off and financially stable a corporation is. It is essential because liabilities suggest that a business must eventually give another organisation financial benefits. Examples of liabilities include debtors, bank loans, and so forth.
Understanding liability
A liability is an obligation one party owes to another that hasn’t been met or paid for. In the field of accounting, a commitment is a financial liability. However, it is more particularly defined by past commercial dealings, occasions, sales, trades of commodities or services, or anything else that will provide income in the future. Current liabilities are considered short-term obligations, whereas non-current liabilities are long-term.
Liabilities are future financial sacrifices that a business must make for other entities as a result of previous occurrences or previous transactions. A company’s liabilities must be managed effectively to prevent a solvency crisis or, in the worst situation, bankruptcy. Liabilities can be classified as current, non-current, or contingent.
Types of liability
Liabilities are primarily categorised based on when they are due. The company’s ability to manage its financial obligations depends on the classification. They are as follows:
- Current liabilities
Current obligations are those with a one-year maturity date. These typically happen throughout regular business activities. Due to the short-term nature of these financial commitments, management should consider the company’s liquidity.
- Non-current liabilities
Obligations that are due after more than a year are referred to as non-current or long-term liabilities. It is crucial that short-term duties, such as short-term loans or the current element of long-term debt, are not included in the non-current liabilities.
- Contingent liabilities
Contingent liabilities are potential liabilities that come to pass in a fictitious incident. These might take place. As a result, only commitments with a larger than 50% likelihood of occurring are recorded in accounting records. Still unresolved liabilities include lawsuits, government inquiries, liquidated damages, and product warranties.
How liabilities work
When you purchase your company, you have two options for paying: cash from your checking account or a loan. Either way, borrowing creates a debt that must be repaid at some point, either in cash or by using other assets.
For instance, using a credit card to make purchases from suppliers is a type of borrowing that, unless paid off at the end of the month, creates a liability for your company. Similar penalties result from obtaining a bank overdraft, a business loan, or a mortgage on real estate used for business purposes. Corporate operations like paying staff and collecting sales tax from clients can also result in liabilities.
Your company’s balance sheet, a financial statement that depicts the state of the business after an accounting period, lists liabilities. The business’s assets, or what it owns, are displayed on the left, while its obligations and owners’ equity are displayed on the right. Typically, the liabilities are shown above the owners’ equity because they will be paid back if a company files for bankruptcy.
Example of liabilities
Examples of liabilities are:
- Defaulted loans
- Plans for paying for purchased equipment
- Supplier payments that are due
- Expenses required for goods or services obtained
- Accrued income (worker compensation not yet paid)
- Interest due on outstanding bonds or preferred shares.
- Unpaid fines or responsibilities to the law
- Unpaid pension contributions
- Client deposits
- Taxes owing
Frequently Asked Questions
Liabilities are a company’s financial obligations, while assets are a company’s resources. Equity is the owner’s investment in the company.
Liabilities and assets are always equal because an equal amount of assets offsets every company’s liability. For example, if a company owes US$1,000 in liabilities, it will have US$1,000 in assets to offset that debt. Equity is the difference between the two, representing the owner’s investment in the company.
In simple terms, liabilities are what a company owes, assets are what a company owns, and equity is the owner’s investment.
A contingent obligation is a duty or potential loss that might exist in the future depending on how a specific event turns out. Investigations that are still open, product warranties, and prospective lawsuits can all lead to contingent liability.
A company’s non-current obligations are those that it anticipates taking longer than current liabilities to pay off. Liabilities are divided into existing and non-current categories on the balance sheet. Non-current commitments are sometimes known as long-term liabilities.
Liabilities are reported on a company’s balance sheet. According to the accounting equation, the total number of penalties must match the difference between the total amount of assets and the total amount of equity. According to accepted accounting rules, liabilities must be declared.
While both assets and liabilities are important financial concepts, there is one key difference between the two: assets represent something of value that a company owns, while liabilities represent something that a company owes. This key difference is important to understand when evaluating a company’s financial position.
Assets are important because they can generate revenue or create value for the company. For example, a company might own a factory that it uses to produce goods. The factory is an asset because it can generate revenue for the company. Liabilities, on the other hand, are important because they represent a financial obligation that a company must pay. For example, a company might have a loan from a bank. The loan is a liability because the company must make payments to the bank.
Related Terms
- Cost of Equity
- Capital Adequacy Ratio (CAR)
- Interest Coverage Ratio
- Industry Groups
- Income Statement
- Historical Volatility (HV)
- Embedded Options
- Dynamic Asset Allocation
- Depositary Receipts
- Deferment Payment Option
- Debt-to-Equity Ratio
- Financial Futures
- Contingent Capital
- Conduit Issuers
- Calendar Spread
- Cost of Equity
- Capital Adequacy Ratio (CAR)
- Interest Coverage Ratio
- Industry Groups
- Income Statement
- Historical Volatility (HV)
- Embedded Options
- Dynamic Asset Allocation
- Depositary Receipts
- Deferment Payment Option
- Debt-to-Equity Ratio
- Financial Futures
- Contingent Capital
- Conduit Issuers
- Calendar Spread
- Devaluation
- Grading Certificates
- Distributable Net Income
- Cover Order
- Tracking Index
- Auction Rate Securities
- Arbitrage-Free Pricing
- Net Profits Interest
- Borrowing Limit
- Algorithmic Trading
- Corporate Action
- Spillover Effect
- Economic Forecasting
- Treynor Ratio
- Hammer Candlestick
- DuPont Analysis
- Net Profit Margin
- Law of One Price
- Annual Value
- Rollover option
- Financial Analysis
- Currency Hedging
- Lump sum payment
- Annual Percentage Yield (APY)
- Excess Equity
- Fiduciary Duty
- Bought-deal underwriting
- Anonymous Trading
- Fair Market Value
- Fixed Income Securities
- Redemption fee
- Acid Test Ratio
- Bid Ask price
- Finance Charge
- Futures
- Basis grades
- Short Covering
- Visible Supply
- Transferable notice
- Intangibles expenses
- Strong order book
- Fiat money
- Trailing Stops
- Exchange Control
- Relevant Cost
- Dow Theory
- Hyperdeflation
- Hope Credit
- Futures contracts
- Human capital
- Subrogation
- Qualifying Annuity
- Strategic Alliance
- Probate Court
- Procurement
- Holding company
- Harmonic mean
- Income protection insurance
- Recession
- Savings Ratios
- Pump and dump
- Total Debt Servicing Ratio
- Debt to Asset Ratio
- Liquid Assets to Net Worth Ratio
- Liquidity Ratio
- Personal financial ratios
- Payroll deduction plan
- Operating expenses
- Demand elasticity
- Deferred compensation
- Conflict theory
- Acid-test ratio
- Withholding Tax
- Benchmark index
- Double Taxation Relief
- Debtor Risk
- Securitization
- Yield on Distribution
- Currency Swap
- Overcollateralization
- Efficient Frontier
- Listing Rules
- Green Shoe Options
- Accrued Interest
- Market Order
- Accrued Expenses
- Target Leverage Ratio
- Acceptance Credit
- Balloon Interest
- Abridged Prospectus
- Data Tagging
- Perpetuity
- Optimal portfolio
- Hybrid annuity
- Investor fallout
- Intermediated market
- Information-less trades
- Back Months
- Adjusted Futures Price
- Expected maturity date
- Excess spread
- Quantitative tightening
- Accreted Value
- Equity Clawback
- Soft Dollar Broker
- Stagnation
- Replenishment
- Decoupling
- Holding period
- Regression analysis
- Wealth manager
- Financial plan
- Adequacy of coverage
- Actual market
- Credit risk
- Insurance
- Financial independence
- Annual report
- Financial management
- Ageing schedule
- Global indices
- Folio number
- Accrual basis
- Liquidity risk
- Quick Ratio
- Unearned Income
- Sustainability
- Value at Risk
- Vertical Financial Analysis
- Residual maturity
- Operating Margin
- Trust deed
- Profit and Loss Statement
- Junior Market
- Affinity fraud
- Base currency
- Working capital
- Individual Savings Account
- Redemption yield
- Net profit margin
- Fringe benefits
- Fiscal policy
- Escrow
- Externality
- Multi-level marketing
- Joint tenancy
- Liquidity coverage ratio
- Hurdle rate
- Kiddie tax
- Giffen Goods
- Keynesian economics
- EBITA
- Risk Tolerance
- Disbursement
- Bayes’ Theorem
- Amalgamation
- Adverse selection
- Contribution Margin
- Accounting Equation
- Value chain
- Gross Income
- Net present value
- Leverage ratio
- Inventory turnover
- Gross margin
- Collateral
- Being Bearish
- Being Bullish
- Commodity
- Exchange rate
- Basis point
- Inception date
- Riskometer
- Trigger Option
- Zeta model
- Racketeering
- Market Indexes
- Short Selling
- Quartile rank
- Defeasance
- Cut-off-time
- Business-to-Consumer
- Bankruptcy
- Acquisition
- Turnover Ratio
- Indexation
- Fiduciary responsibility
- Benchmark
- Pegging
- Illiquidity
- Backwardation
- Backup Withholding
- Buyout
- Beneficial owner
- Contingent deferred sales charge
- Exchange privilege
- Asset allocation
- Maturity distribution
- Letter of Intent
- Emerging Markets
- Consensus Estimate
- Cash Settlement
- Cash Flow
- Capital Lease Obligations
- Book-to-Bill-Ratio
- Capital Gains or Losses
- Balance Sheet
- Capital Lease
Most Popular Terms
Other Terms
- Bond Convexity
- Compound Yield
- Brokerage Account
- Discretionary Accounts
- Industry Groups
- Growth Rate
- Green Bond Principles
- Gamma Scalping
- Funding Ratio
- Free-Float Methodology
- Foreign Direct Investment (FDI)
- Floating Dividend Rate
- Flight to Quality
- Real Return
- Protective Put
- Perpetual Bond
- Option Adjusted Spread (OAS)
- Non-Diversifiable Risk
- Merger Arbitrage
- Liability-Driven Investment (LDI)
- Income Bonds
- Guaranteed Investment Contract (GIC)
- Flash Crash
- Equity Carve-Outs
- Cost Basis
- Deferred Annuity
- Cash-on-Cash Return
- Earning Surprise
- Bubble
- Beta Risk
- Bear Spread
- Asset Play
- Accrued Market Discount
- Ladder Strategy
- Junk Status
- Intrinsic Value of Stock
- Interest-Only Bonds (IO)
- Inflation Hedge
- Incremental Yield
- Industrial Bonds
- Holding Period Return
- Hedge Effectiveness
- Flat Yield Curve
- Fallen Angel
- Exotic Options
- Execution Risk
- Exchange-Traded Notes
- Event-Driven Strategy
- Eurodollar Bonds
- Enhanced Index Fund
Know More about
Tools/Educational Resources
Markets Offered by POEMS
Read the Latest Market Journal
Company Overview Yangzijiang Maritime Development Ltd (YZJ Maritime) operates as a maritime financial solutions provider, spun off from Yangzijiang Financial Holding Ltd and listed on the SGX Mainboard in November 2025. The company manages a diversified fleet of over 80 vessels with newbuilding orders for up to 50 additional vessels across Chinese shipyards. Led by Executive Chairman and CEO Mr Ren Yuanlin, who brings over 50 years of experience in shipbuilding and finance, the Group serves as a strategic hub connecting shipyards, shipowners, charterers, and capital markets. Investment Merits and Strategic Positioning YZJ Maritime's unique positioning allows it to capture economic value across the entire vessel lifecycle. The company generates revenue through multiple streams: procurement margins at build stage (up to 20% below first-tier shipyard prices), charter income during vessel operation, interest on finance leases, and capital gains upon exit. This comprehensive approach spans across tankers, gas carriers, bulkers, containerships, and offshore support vessels. The company's diversified portfolio demonstrates strong risk management capabilities, maintaining a zero non-performing loan track record over three years across its extensive fleet operations. In FY25, the Group generated US$32.3mn in charter income, US$33.2mn from finance lease interest, and US$13.7mn in capital gains from joint venture vessel sales. Shipping Cycle Capitalisation YZJ Maritime is strategically positioned to benefit from the current shipping cycle upswing, with vessel prices reaching 15-year highs and increasing 95% year-on-year. This favourable market environment has accelerated the company's transition from lower-margin cash management activities to higher-returning maritime assets. Maritime Business income surged 61% to US$69.9mn, now representing 49% of total income compared to 29% in FY24, whilst Cash Management income declined 56% to US$33.5mn. Financial Strength and Growth Potential The Group maintains exceptional financial strength with US$400mn in cash, zero borrowings, and total liabilities representing just 3.1% of total assets. Net cash of approximately S$507mn represents 26.9% of market capitalisation, providing substantial financial flexibility. The company's unleveraged position offers significant upside potential, with management planning to introduce leverage through bank borrowings, convertible notes, and asset-backed loans, potentially boosting project internal rates of return from the current 10-15% to 20-30%. Research Recommendation Phillip Securities Research initiates coverage with a BUY rating and target price of S$0.69, based on a 1.0x price-to-book FY26e valuation. This represents an 11% premium to peer valuations of 0.9x price-to-book, justified by the Group's substantial net cash position, rapid book value growth trajectory from S$0.5bn to S$2.0bn in net assets over three years, and differentiated positioning as a full-lifecycle maritime financial platform. Frequently Asked Questions Q: What is YZJ Maritime's core business model? A: YZJ Maritime operates as a maritime financial solutions provider that captures value across the entire vessel lifecycle, from newbuilding procurement to charter operations, financing, and eventual capital gains on exit across various vessel types. Q: How has the shipping cycle affected YZJ Maritime's business mix? A: The shipping cycle upswing has accelerated YZJ Maritime's transition from cash management to maritime assets. Maritime Business income surged 61% to US$69.9mn and now contributes 49% of total income, whilst Cash Management income fell 56% to US$33.5mn. Q: What is Phillip Securities Research's recommendation and target price? A: Phillip Securities Research initiates coverage with a BUY rating and target price of S$0.69, pegged to 1.0x P/B FY26e, representing an 11% premium to peer valuations. Q: How strong is YZJ Maritime's financial position? A: The Group maintains US$400mn in cash with zero borrowings and total liabilities of just 3.1% of total assets. Net cash of S$507mn represents 26.9% of market capitalisation. Q: What growth opportunities exist for the company? A: Management plans to introduce leverage through various financing methods, potentially boosting project IRRs from 10-15% to 20-30%. The company also has up to 50 newbuilds in the pipeline with US$1.3bn across two funds. Q: How diversified is YZJ Maritime's vessel portfolio? A: The Group operates across tankers, gas carriers, bulkers, containerships, and offshore support vessels, managing 80+ vessels with a zero NPL track record over three years. Q: What market conditions support the investment thesis? A: Vessel prices are at multi-year highs (+95% YoY), the Baltic Dry Index is at approximately 2,000 (+22% YoY), and the shipping cycle upswing provides favourable conditions for maritime asset deployment. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Software Sector Shows Resilience Despite AI Concerns, Analyst Maintains Overweight Rating
Strong Revenue Growth Signals Recovery The software sector has faced significant headwinds in 2025, declining 24% year-to-date compared to the S&P 500's more modest 7.5% drop. The sector sits 34% below its mid-September 2025 peak, primarily driven by concerns over AI disruption and decelerating revenue growth. This downturn represents the fourth-largest decline in the sector's history, trailing only the dot-com bubble crash (-63%), the Global Financial Crisis (-50%), and the post-COVID technology selloff (-46%). However, beneath the surface volatility, fundamental performance indicators suggest the sector's underlying strength remains intact. Software growth has demonstrated notable reacceleration since mid-2023, with last twelve months total revenue climbing 15% year-over-year in the fourth quarter of 2025. This marks the highest growth rate since early 2023 and represents a significant 4 percentage point improvement from the 11% recorded a year earlier, when excluding cloud providers from the analysis. Large-Cap Outperformance Drives Sector Dynamics A clear bifurcation has emerged within the software landscape, with large-cap Software-as-a-Service (SaaS) companies significantly outperforming their smaller counterparts. Large-cap firms are demonstrating a 7 percentage point advantage over smaller peers amid ongoing AI disruption concerns. These established players recorded revenue growth of 17% year-over-year in the fourth quarter of 2025, compared to 12% in the same period of 2024, with expectations for this 17% growth rate to continue into the first quarter of 2026. Strategic AI Positioning Supports Investment Case The analyst maintains an overweight rating on the software sector, citing strategic positioning around artificial intelligence adoption. Large-cap software companies are prioritising AI usage growth over aggressive upselling of premium packages, demonstrating a measured approach to monetisation. Clear revenue generation pathways have emerged through premium stock keeping units (SKUs) and generative credit consumption via usage-based pricing models. This strategic shift away from traditional seat-based subscription models provides crucial protection against revenue erosion from industry-wide layoffs. The current valuation environment presents an attractive entry point, with the EV/Sales ratio for large-cap SaaS companies trading below the negative one standard deviation level of 9.4, despite rising software revenue and net income performance. Frequently Asked Questions Q: How has the software sector performed compared to broader markets in 2025? A: The software sector has declined 24% year-to-date, significantly underperforming the S&P 500's 7.5% drop, and sits 34% below its mid-September 2025 peak. Q: What are the main factors driving the software sector decline? A: The primary drivers are AI disruption concerns and slowing revenue growth, making this the fourth-largest sector decline historically. Q: How does current revenue growth compare to previous periods? A: Software revenue growth has reaccelerated to 15% year-over-year in Q4 2025, the highest since early 2023 and 4 percentage points above the 11% recorded a year ago. Q: Are large-cap and small-cap software companies performing similarly? A: No, large-cap SaaS companies are outperforming smaller peers by 7 percentage points, with large-cap revenue up 17% year-over-year versus 12% in the prior year. Q: What is the analyst's recommendation on the software sector? A: The analyst maintains an overweight rating on the software sector despite recent volatility. Q: How are software companies adapting their AI strategies? A: Large-cap companies are prioritising AI usage growth over aggressive premium package upselling, focusing on clear monetisation routes through premium SKUs and usage-based pricing. Q: What protection do companies have against industry layoffs? A: The shift from seat-based subscriptions to usage-based pricing models helps protect revenue from industry-wide employment reductions. Q: How attractive are current valuations? A: The EV/Sales ratio for large-cap SaaS is trading below the negative 1 standard deviation level of 9.4, despite rising revenue and net income, suggesting attractive valuations. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Market Performance Review Singapore equities concluded a remarkable ten consecutive months of gains with a 2.2% decline in March, though the first quarter of 2026 still delivered a positive 5.1% return. The market reached all-time highs on 23rd February before the Iran war drove significant sector rotation, boosting performance in defence spending, biofuels, and capital markets. Banks demonstrated resilience, maintaining gains even during March's decline and outperforming throughout the quarter with their stable dividend yields. However, REITs faced substantial pressure as interest rate expectations shifted from anticipated cuts to potential rate hikes. Consumer segments also weakened as rising inflation compressed disposable income. Strategic Outlook: Capital Preservation in Volatile Times Phillip Securities Research adopts a cautious stance, emphasising capital preservation over prediction in the current uncertain environment. Equities have transformed into volatile, leveraged instruments tied to oil price movements. The closure of the Straits of Hormuz presents dual risks: driving higher energy prices and inflation whilst threatening global production through material shortages. The current conflict's impact could exceed previous disruptions. Unlike pandemic-era bottlenecks affecting vessel availability, the present situation threatens feedstock and raw material supplies. Singapore has already experienced force majeures at chemical facilities, affecting industries from plastics to pharmaceuticals. Historical precedent suggests oil prices could reach US$200 per barrel, based on the Kuwait war pattern when crude oil surged 275% from US$15 to US$42. Investment Recommendations: Capitalising on Capex Cycles Despite geopolitical uncertainties, Phillip Securities Research identifies opportunities within expanding global capital expenditure cycles. Key sectors include data centres, with hyperscalers increasing AI and data centre capex by approximately 60% in 2026. Singapore's recent 200MW data centre application request in Jurong reflects this trend. The semiconductor sector benefits from AI and memory chip demand driving foundry capacity expansion. Defence spending increases as countries prioritise domestic military capabilities, whilst renewable energy gains importance for energy security. Singapore's construction sector enjoys multi-year demand growth. Primary beneficiaries include IT service companies like Telechoice, bidding for regional data centre projects, and Frencken, positioned to benefit from semiconductor equipment demand. Oiltek targets sustainable aviation fuel opportunities. Conversely, REITs face near-term underweight recommendations due to stagflationary pressures affecting rents, interest expenses, and valuations. Singapore's macro fundamentals remain robust, with semiconductor exports surging 51% in February and loan growth reaching 6.3%, the fastest in over four years. Building materials demand shows strength with ready-mixed concrete up 47% year-on-year. Frequently Asked Questions Q: What caused Singapore equities to decline in March 2026? A: Singapore equities fell 2.2% in March, ending ten consecutive months of gains, primarily due to the Iran war's impact on global markets and sector rotation towards defence, biofuels, and capital markets. Q: How are Singapore banks performing compared to other sectors? A: Banks demonstrated resilience by maintaining gains even during March's market decline and outperformed throughout the quarter, supported by their stable dividend yields. Q: What is Phillip Securities Research's investment strategy recommendation? A: The research house advocates for capital preservation over prediction, emphasising that equities have become volatile instruments tied to oil price movements, making cautious positioning essential. Q: Which sectors are expected to benefit from current global developments? A: Key beneficiary sectors include data centres, semiconductors, defence, renewable energy, and construction, all driven by expanding global capital expenditure cycles accelerated by geopolitical tensions. Q: What are the risks to oil prices from the current conflict? A: Oil prices could potentially reach US$200 per barrel based on historical precedent from the Kuwait war, when crude oil surged 275% from US$15 to US$42 due to supply disruptions. Q: How is Singapore's domestic economy performing? A: Singapore shows strong macro fundamentals with semiconductor exports up 51% in February, loan growth at 6.3% (fastest in four years), and building materials demand surging with concrete up 47% year-on-year. Q: Which specific companies are positioned to benefit from current trends? A: Telechoice is bidding for regional data centre projects, Frencken will benefit from semiconductor equipment demand, and Oiltek is targeting sustainable aviation fuel opportunities. Q: Why are REITs facing pressure in the current environment? A: REITs are experiencing headwinds due to shifting interest rate expectations from cuts to potential hikes, creating a stagflationary environment that pressures rents, increases interest expenses, and compresses valuations. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Interest Rates Hit 45-Month Low Singapore's banking sector faces a mixed outlook as interest rates continue their downward trajectory whilst geopolitical tensions create market volatility. March's 3M-SORA declined 5 basis points month-on-month to 1.09%, marking the lowest level since July 2022. This represents a significant 153 basis points year-on-year decline, though notably, the decline is also the smallest yearly decrease in nine months. The interest rate environment reflects Singapore's status as a "safe haven" destination, with capital inflows driving FX reserves up 10% year-on-year in February 2026. However, analysts expect the 3M-SORA decline to moderate for the remainder of the year as Middle East conflict concerns reduce expectations for Federal Reserve rate cuts. Banking Fundamentals Show Resilience Despite the challenging rate environment, Singapore banks demonstrate solid underlying fundamentals. Loan growth continues its upward trajectory, with February 2026 figures showing 6.3% growth, whilst banks guide for low to mid-single digit expansion. Current Account and Savings Account (CASA) deposits rose 11% year-on-year, with the CASA ratio improving to 20% from 19.8% in January 2025. This improvement provides a crucial tailwind for banks by lowering funding costs and cushioning net interest margin compression. The sector's exposure to potential regional risks appears well-contained. Trade, Services and Commodities loans, including Oil & Gas exposure, represent only approximately 7% of total gross loans across the three major banks. Sector non-performing loan ratios remain benign at 0.3-2.0%, whilst ASEAN loan growth averages low-to-mid single digits year-on-year, suggesting limited risk from Middle East conflicts. Market Outlook and Investment Preference The escalation of Iran conflict and oil prices surging past US$100 per barrel have prompted the Federal Reserve to raise its 2026 PCE inflation forecast to 2.7%. Markets now price in zero rate cuts for the remainder of 2026, creating a higher-for-longer rate backdrop that supports net interest margins. Quarter-on-quarter NIM stabilisation is already evident at OCBC and UOB in Q4 2025. Heightened market volatility continues benefiting capital markets income and wealth management fees, providing meaningful offset to net interest income headwinds. Banks maintain attractive dividend yields at 4.9%, with ongoing buybacks improving return on equity. The research maintains a NEUTRAL sector rating, expressing preference for DBS due to its fixed-dividend policy and OCBC for wealth management growth and excess capital. Frequently Asked Questions Q: What is the current level of Singapore's 3M-SORA and how does it compare historically? A: March's 3M-SORA stands at 1.09%, representing the lowest level in 45 months since July 2022. It declined 5 basis points month-on-month and 153 basis points year-on-year. Q: How are Singapore banks performing in terms of loan growth? A: Singapore loan growth continues climbing, with February 2026 showing 6.3% growth. Banks are guiding for low to mid-single digit growth going forward. Q: What is the banks' exposure to potential Middle East conflict risks? A: Singapore banks' TSC loans, including O&G exposure, represent only approximately 7% of total gross loans in aggregate, with sector NPL ratios remaining benign at 0.3-2.0% across the three banks. Q: How are deposit trends affecting the banking sector? A: CASA deposits rose 11% year-on-year with the CASA ratio improving to 20% from 19.8% in January 2025, providing a tailwind by lowering funding costs and cushioning NIM compression. Q: What is the research recommendation for Singapore banks? A: The research maintains a NEUTRAL rating on the sector, with preference for DBS due to its fixed-dividend policy and OCBC for wealth management growth and excess capital. Q: How are current market conditions affecting bank revenues? A: Heightened market volatility benefits capital markets income and wealth management fees, providing meaningful offset to net interest income headwinds from the rate environment. Q: What are the dividend prospects for Singapore banks? A: Banks maintain attractive dividend yields at 4.9%, with ongoing buybacks improving return on equity, making them appealing for income-focused investors. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Oil ETF Set to Continue Outperformance in April as Most Asset Classes Face Headwinds
Exchange-traded funds (ETFs) experienced a challenging March, with most asset classes posting negative returns as market volatility persisted across global markets. However, oil and Bitcoin emerged as notable exceptions, demonstrating resilience amid broader market weakness. Mixed Performance Across Asset Classes in March The commodity sector provided the standout performance in March, with the SPDR S&P Oil & Gas Exploration & Production ETF (XOP) surging 18.7% for its third consecutive monthly gain. This impressive rally maintained oil's uptrend trajectory, positioning it as the clear winner amongst major asset classes. Bitcoin also bucked the broader negative trend, with the ProShares Bitcoin Strategy ETF (BITO) gaining 2.9% during the month. This positive performance helped snap a four-month losing streak, though the cryptocurrency remains in a broader downtrend pattern. Conversely, precious metals faced significant headwinds, with the SPDR Gold MiniShares Trust (GLDM) tumbling 10.9% in March. This sharp decline snapped a seven-month winning streak for gold, marking it as the month's worst performer. Traditional equity markets also struggled, with the Vanguard S&P 500 ETF (VOO) declining 5.0% for its second consecutive monthly retreat. Similarly, the Hang Seng China Enterprises Index ETF fell 5.9%, extending its weakness into a second consecutive month. Outlook for April Points to Continued Oil Strength Looking ahead to April, technical analysis suggests oil is positioned to extend its outperformance relative to other asset classes. The oil ETF is expected to continue its upward momentum, with potential to test the US$202 level, representing a 13.6% upside from current prices. Meanwhile, several asset classes are expected to face continued pressure. Both the S&P 500 and gold ETFs are anticipated to extend their March weakness, with potential retests of key support levels. The S&P 500 ETF may challenge the US$464.30 swing low established in July 2025, whilst gold could retest the US$86.09 support level formed in March 2026. Other asset classes, including US Treasury bonds, Bitcoin, and Singapore equities, are expected to remain rangebound in April, trading within established consolidation patterns as markets await clearer directional catalysts. Frequently Asked Questions Q: Which ETF performed best in March? A: The SPDR S&P Oil & Gas Exploration & Production ETF (XOP) was the top performer, surging 18.7% for its third consecutive monthly gain. Q: What was the worst-performing asset class in March? A: Gold was the worst performer, with the SPDR Gold MiniShares Trust (GLDM) tumbling 10.9%, snapping a seven-month winning streak. Q: Which asset class is expected to continue outperforming in April? A: Oil is expected to continue outperforming other asset classes in April, with potential to test the US$202 level representing a 13.6% upside. Q: What is the outlook for Bitcoin in April? A: Bitcoin is expected to remain rangebound in April despite gaining 2.9% in March and snapping a four-month losing streak. Q: How did US equities perform in March? A: US equities struggled, with the S&P 500 ETF declining 5.0% for its second consecutive monthly retreat and entering a range consolidation pattern. Q: What support levels are being watched for major indices? A: The S&P 500 ETF may test the US$464.30 swing low from July 2025, while gold could retest the $86.09 support level formed in March 2026. Q: Which asset classes are expected to remain sideways in April? A: US Treasury bonds, Bitcoin, and Singapore equities are all expected to remain rangebound in April, trading within established consolidation patterns. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
iX Biopharma – The Year of the Unicorn , BUY Rating with S$1.00 Target Price
Company Overview iX Biopharma Ltd is a pharmaceutical company founded in 2008 and listed on SGX Catalist in 2015. The company specialises in proprietary drug delivery technologies, WaferiX and WaferlogiX, which enable sublingual delivery of therapeutics with enhanced bioavailability and rapid absorption. With a pipeline of over 30 pharmaceutical drugs and 7 nutraceutical products, iX operates a manufacturing facility in Melbourne, Australia. The company's lead drug, Wafermine, is a ketamine-based wafer for pain management that has successfully completed Phase 2b clinical trials. Major DoD Funding Validates Technology Platform iX Biopharma has achieved a significant milestone by securing US$41 million in funding from the US Department of Defence (DoD), representing a watershed event that de-risks Wafermine's final Phase 3 development. This funding validates the WaferiX technology platform and provides entry into the US$5-6 billion acute pain market in the United States. The DoD endorsement serves as major external validation of the company's sublingual technology, offering a superior outcome compared to typical Phase 2 out-licensing deals where partners capture the majority of upside. Immediate Revenue Potential The near-term revenue driver centres on supplying Wafermine to the DoD under an Emergency Use Authorisation for immediate battlefield deployment and operational military medical use. Initial orders of US$3 million are expected in FY27e. The larger opportunity lies in Wafermine adoption into standard field kits and sales into the non-military commercial market following full US FDA approval. Additionally, iX is monetising its compound pharmacy operations in the US market, worth US$6 billion. Through partnership with Orion Specialty Labs, the company can supply personalised drugs via a capital-light manufacturing and distribution route, with NAD+ (nicotinamide adenine dinucleotide) serving as the near-term revenue driver. Investment Recommendation Phillip Securities Research has re-initiated coverage on iX Biopharma with a BUY recommendation and a sum-of-the-parts derived target price of S$1.00. The research identifies three pathways to monetise Wafermine: full commercialisation upon FDA approval in 1Q29, out-licensing, or an outright sale of the drug. Until Phase 3 trial completion, iX Bio will benefit from three new revenue sources through Wafermine EUA sales, DoD grant funding, and compound pharmacy operations in the US. Frequently Asked Questions Q: What is the significance of the US DoD funding for iX Biopharma? A: The US$41 million DoD funding represents a watershed event that de-risks Wafermine's Phase 3 development, validates the WaferiX technology platform, and provides access to the US$5-6 billion acute pain market whilst allowing iX to retain full ownership and control. Q: When are initial DoD orders expected and what revenue potential exists? A: Initial orders of US$3 million are expected in FY27e under Emergency Use Authorisation. The larger opportunity involves standard field kit adoption and commercial market sales following FDA approval. Q: What is iX Biopharma's core business and technology? A: iX Biopharma is a pharmaceutical company with proprietary WaferiX and WaferlogiX drug delivery technologies enabling sublingual delivery of therapeutics with enhanced bioavailability and rapid absorption, with a pipeline of over 30 pharmaceutical drugs and 7 nutraceuticals. Q: What are the three pathways to monetise Wafermine? A: The three pathways are full commercialisation upon FDA approval in 1Q29, out-licencing the drug to partners, or an outright sale of Wafermine to interested parties. Q: How does the compound pharmacy strategy contribute to revenue? A: The US compound pharmacy market is worth US$6 billion. Through partnership with Orion Specialty Labs, iX can supply personalised drugs using WaferiX technology without further FDA approvals, with NAD+ as the near-term revenue driver. Q: What is Phillip Securities Research's recommendation and target price? A: Phillip Securities Research has issued a BUY recommendation with a sum-of-the-parts derived target price of S$1.00, applying a 40% discount to Wafermine's net present value and valuing the compound pharmacy at 20x PE. Q: What other revenue sources will iX benefit from before Phase 3 completion? A: Until Phase 3 trial completion, iX will enjoy three new revenue sources: Wafermine EUA sales to the DoD, DoD grant funding for development, and compound pharmacy operations in the US market. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Strategic Divestment to Enhance Portfolio Quality First REIT has announced a comprehensive divestment strategy for its Indonesian healthcare assets, proposing to sell eight hospitals and three non-hospital properties for S$471.5mn. The purchaser, PT Siloam International Hospitals Tbk, will acquire these assets in the first tranche of what represents a strategic pivot towards developed markets. Company Overview First REIT operates as a healthcare-focused real estate investment trust with assets spanning Singapore, Japan, and Indonesia. The REIT specialises in healthcare properties including hospitals and medical facilities across the Asia-Pacific region. Two-Tranche Divestment Structure The proposed transaction follows a carefully structured two-phase approach. The initial tranche involves eleven Indonesian assets valued at S$471.5mn, comprising eight hospitals for IDR5.1tn (S$389.2mn) and three non-hospital assets for IDR1.1tn (S$82.4mn). This pricing represents a 2.1% premium over the average of two recent independent valuations. Additionally, First REIT has secured a put option for the remaining six Indonesian hospitals, valued at S$294.8mn, exercisable until 31 October 2026. This structure provides flexibility whilst ensuring complete exit from the Indonesian market if desired. Financial Impact and Capital Allocation The divestment will generate significant financial benefits for unitholders. The S$9.7mn premium over appraised value will be distributed as special dividends over two quarters following completion. The manager has waived its S$2.4mn divestment fee to align with unitholder interests. Net proceeds of S$464.2mn will primarily reduce debt, with S$362.7mn (78%) allocated to debt repayment. This will dramatically improve the REIT's leverage profile, reducing aggregate leverage from 42.1% to 16.7%. The remaining debt will largely comprise lower-cost JPY-denominated borrowings. Strategic Outlook and Research Recommendation The divestment addresses rental arrears issues whilst enabling capital recycling from non-core assets. First REIT plans to focus on assets in Singapore and Japan whilst pursuing expansion opportunities in developed markets, which offer lower equity risk premiums, reduced debt costs, and more stable currencies. Phillip Securities Research maintains an ACCUMULATE recommendation with a revised target price of S$0.25, down from S$0.29. The valuation methodology has shifted to 1x FY25 P/NAV from the dividend discount model, reflecting uncertainty over future portfolio composition pending the strategic review. Frequently Asked Questions Q: What assets is First REIT proposing to divest? A: First REIT is proposing to divest eight hospitals and three non-hospital assets in Indonesia for S$471.5mn, with an additional put option for six remaining hospitals at S$294.8mn. Q: Who is purchasing the Indonesian assets? A: PT Siloam International Hospitals Tbk (Siloam) is the purchaser of the eight hospitals in the first tranche. Q: When will the divestment be completed? A: The divestments are subject to unitholders' approval at an Extraordinary General Meeting scheduled for June 2026, with targeted completion in August 2026. Q: How will the proceeds be used? A: Net proceeds of S$464.2mn will primarily reduce debt (S$362.7mn or 78%), with S$9.7mn distributed as special dividends and the remainder allocated to capital expenditure and working capital. Q: What is Phillip Securities Research's recommendation and target price? A: Phillip Securities Research maintains ACCUMULATE with a lower target price of S$0.25, reduced from the previous S$0.29. Q: How will the divestment impact leverage? A: Aggregate leverage would decline significantly to 16.7% from the current 42.1%, assuming completion on 31 December 2025. Q: What is First REIT's strategic direction following the divestment? A: First REIT plans to focus on Singapore and Japan assets whilst transitioning toward developed markets, which offer lower equity risk premiums, lower debt costs, and more stable currencies. Q: Will unitholders receive any special distributions? A: Yes, the S$9.7mn premium over appraised value will be distributed as special dividends over two quarters following completion of the divestment. This article has been auto-generated using AI tools. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
Company Overview The CSOP iEdge S-REIT Leaders Index ETF (SRT) is an exchange-traded fund that provides diversified exposure to Singapore's real estate investment trust market. The ETF maintains a well-balanced portfolio across eight sectors, with industrial properties representing the largest allocation at 29.3%, followed by office properties at 20.1%. This diversification strategy positions the fund to capture broad-based performance across Singapore's REIT landscape. Valuation Methodology and Target Price Revision Phillip Securities Research employs a dual valuation approach for SRT, utilising both historical dividend yield spread analysis and price-to-book ratio methodologies. These approaches yield target prices of S$0.77 and S$0.74 respectively. By applying equal weightage to both valuation methods, the research house has established a revised target price of S$0.755, representing a decrease from the previous target of S$0.815. Despite this downward adjustment, Phillip Securities Research maintains its ACCUMULATE recommendation for the ETF. Portfolio Composition Changes Recent portfolio rebalancing has resulted in changes to SRT's top holdings. CapitaLand Ascendas REIT and CapitaLand Integrated Commercial Trust have secured positions among the top three holdings, displacing Mapletree Logistics Trust and Mapletree Industrial Trust. Keppel DC REIT maintains its presence in the portfolio, albeit with a marginally reduced weighting. These changes reflect the dynamic nature of the Singapore REIT market and the fund's responsive allocation strategy. Market Environment and Outlook The Federal Reserve's recent communications suggest that energy price pressures are unlikely to significantly impact the broader inflation trajectory, whilst maintaining flexibility for potential future rate cuts. This monetary policy stance creates an increasingly favourable environment for Singapore REITs. Lower anticipated funding costs are expected to serve as a tailwind for earnings performance and provide support for distribution per unit growth extending into FY26. This improved cost environment should benefit the underlying REITs within SRT's portfolio, potentially enhancing the fund's overall performance prospects. Frequently Asked Questions What is Phillip Securities Research's recommendation and target price for SRT? Phillip Securities Research maintains an ACCUMULATE recommendation with a target price of S$0.755, down from the previous target of S$0.815. How does Phillip Securities Research value the CSOP iEdge S-REIT Leaders Index ETF? The research house uses a combination of historical dividend yield spread and price-to-book ratios, yielding target prices of S$0.77 and S$0.74 respectively, with equal weightage applied to both methods. Which REITs have entered the top three holdings recently? CapitaLand Ascendas REIT and CapitaLand Integrated Commercial Trust have entered the top three holdings, replacing Mapletree Logistics Trust and Mapletree Industrial Trust. What is the sector allocation of SRT? SRT is diversified across eight sectors, with industrial being the largest at 29.3% and office being the second-largest at 20.1%. How might Federal Reserve policy impact Singapore REITs? The Fed's indication that energy price pressures won't derail inflation outlook whilst keeping the path open for rate cuts creates a more favourable environment for S-REITs through lower funding costs. What is the outlook for distribution per unit growth? Lower funding costs ahead are expected to provide a tailwind to earnings and support DPU growth into FY26. Has Keppel DC REIT maintained its position in the portfolio? Yes, Keppel DC REIT remains in the portfolio but at a slightly lower weight than before. This article has been auto-generated using AI tools. It is based on a report by a Phillip Securities Research analyst. Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
